

1 A bill to be entitled

2 An act relating to nonresident sterile compounding
3 permits; amending s. 465.003, F.S.; defining the terms
4 "compounding" and "outsourcing facility"; amending s.
5 465.0156, F.S.; conforming provisions to changes made
6 by the act; expanding penalties to apply to injury to
7 a nonhuman animal; deleting a requirement that the
8 Board of Pharmacy refer regulatory issues affecting a
9 nonresident pharmacy to the state where the pharmacy
10 is located; providing that a pharmacy is subject to
11 certain health care fraud provisions; creating s.
12 465.0158, F.S.; requiring registered nonresident
13 pharmacies and outsourcing facilities to obtain a
14 permit in order to ship, mail, deliver, or dispense
15 compounded sterile products into this state; requiring
16 submission of an application and a nonrefundable fee;
17 providing application requirements; authorizing the
18 board to deny, revoke, or suspend a permit, or impose
19 a fine or reprimand for certain actions; providing
20 dates by which certain nonresident pharmacies must
21 obtain a permit; authorizing the board to adopt rules;
22 amending s. 465.017, F.S.; authorizing the department
23 to inspect nonresident pharmacies and nonresident
24 sterile compounding permittees; requiring such
25 pharmacies and permittees to pay for the costs of such
26 inspections; providing an effective date.

Page 1 of 9

CODING: Words ~~stricken~~ are deletions; words underlined are additions.

hb7077-01-c1

27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52

Be It Enacted by the Legislature of the State of Florida:

Section 1. Subsections (18) and (19) are added to section 465.003, Florida Statutes, to read:

465.003 Definitions.—As used in this chapter, the term:

(18) "Compounding" means combining, mixing, or altering the ingredients of one or more drugs or products to create another drug or product.

(19) "Outsourcing facility" means a single physical location registered as an outsourcing facility under the federal Drug Quality and Security Act, Pub. L. No. 113-54, at which sterile compounding of a drug or product is conducted.

Section 2. Subsections (4) and (5) of section 465.0156, Florida Statutes, are amended, present subsections (6) through (8) are renumbered as subsections (7) through (9), respectively, and a new subsection (6) is added to that section, to read:

465.0156 Registration of nonresident pharmacies.—

(4) The board may deny, revoke, or suspend registration of, or fine or reprimand, a nonresident pharmacy for failure to comply with s. 465.0158, s. 465.017(2), or s. 465.025, or with any requirement of this section in accordance with ~~the provisions of~~ this chapter.

(5) In addition to the prohibitions of subsection (4) the board may deny, revoke, or suspend registration of, or fine or reprimand, a nonresident pharmacy in accordance with ~~the~~

53 ~~provisions of this chapter for conduct which causes or could~~
54 ~~cause serious bodily injury or ~~serious~~ psychological injury to a~~
55 ~~human or serious bodily injury to a nonhuman animal in resident~~
56 ~~of this state if the board has referred the matter to the~~
57 ~~regulatory or licensing agency in the state in which the~~
58 ~~pharmacy is located and the regulatory or licensing agency fails~~
59 ~~to investigate within 180 days of the referral.~~

60 (6) A nonresident pharmacy is subject to s. 456.0635.

61 Section 3. Section 465.0158, Florida Statutes, is created
62 to read:

63 465.0158 Nonresident sterile compounding permit.—

64 (1) In order to ship, mail, deliver, or dispense, in any
65 manner, a compounded sterile product into this state, a
66 nonresident pharmacy registered under s. 465.0156, or an
67 outsourcing facility, must hold a nonresident sterile
68 compounding permit. For purposes of this section, an outsourcing
69 facility as defined in s. 465.003 is a nonresident facility that
70 is not a pharmacy.

71 (2) An application for a nonresident sterile compounding
72 permit shall be submitted on a form furnished by the board. The
73 board may require such information as it deems reasonably
74 necessary to carry out the purposes of this section. The fee for
75 an initial permit and biennial renewal of the permit shall be
76 set by the board pursuant to s. 465.022(14).

77 (3) An applicant must submit the following to the board to
78 obtain an initial permit, or to the department to renew a

79 permit:

80 (a) Proof of registration as an outsourcing facility with
 81 the Secretary of the United States Department of Health and
 82 Human Services if the applicant is eligible for such
 83 registration pursuant to the federal Drug Quality and Security
 84 Act, Pub. L. No. 113-54.

85 (b) Proof of registration as a nonresident pharmacy,
 86 pursuant to s. 465.0156, unless the applicant is an outsourcing
 87 facility, in which case the application must include proof of an
 88 active and unencumbered license, permit, or registration issued
 89 by the state, territory, or district in which the outsourcing
 90 facility is physically located which allows the outsourcing
 91 facility to engage in compounding and to ship, mail, deliver, or
 92 dispense a compounded sterile product into this state.

93 (c) Written attestation by an owner or officer of the
 94 applicant, and by the applicant's prescription department
 95 manager or pharmacist in charge, that:

96 1. The attestor has read and understands the laws and
 97 rules governing sterile compounding in this state.

98 2. A compounded sterile product shipped, mailed,
 99 delivered, or dispensed into this state meets or exceeds this
 100 state's standards for sterile compounding.

101 3. A compounded sterile product shipped, mailed,
 102 delivered, or dispensed into this state must not have been, and
 103 may not be, compounded in violation of the laws and rules of the
 104 state, territory, or district in which the applicant is located.

105 (d) The applicant's existing policies and procedures for
106 sterile compounding, which must comply with pharmaceutical
107 standards in chapter 797 of the United States Pharmacopoeia and
108 any standards for sterile compounding required by board rule or
109 current good manufacturing practices for an outsourcing
110 facility.

111 (e) A current inspection report from an inspection
112 conducted by the regulatory or licensing agency of the state,
113 territory, or district in which the applicant is located. The
114 inspection report must reflect compliance with this section. An
115 inspection report is current if the inspection was conducted
116 within 6 months before the date of submitting the application
117 for the initial permit or within 1 year before the date of
118 submitting an application for permit renewal. If the applicant
119 is unable to submit a current inspection report conducted by the
120 regulatory or licensing agency of the state, territory, or
121 district in which the applicant is located, due to acceptable
122 circumstances, as established by rule, or if an inspection has
123 not been performed, the department shall:

124 1. Conduct, or contract with an entity to conduct, an
125 onsite inspection for which all costs shall be borne by the
126 applicant;

127 2. Accept a current and satisfactory inspection report, as
128 determined by rule, from an entity approved by the board; or

129 3. Accept a current inspection report from the United
130 States Food and Drug Administration conducted pursuant to the

131 federal Drug Quality and Security Act, Pub. L. No. 113-54.
 132 (4) A permittee may not ship, mail, deliver, or dispense a
 133 compounded sterile product into this state if the product was
 134 compounded in violation of the laws or rules of the state,
 135 territory, or district in which the permittee is located or does
 136 not meet or exceed this state's sterile compounding standards.
 137 (5) In accordance with this chapter, the board may deny,
 138 revoke, or suspend the permit of, fine, or reprimand a permittee
 139 for:
 140 (a) Failure to comply with this section;
 141 (b) A violation listed under s. 456.0635, s. 456.065, or
 142 s. 456.072, except s. 456.072(1)(s) and (1)(u);
 143 (c) A violation under s. 465.0156(5); or
 144 (d) A violation listed under s. 465.016.
 145 (6) A nonresident pharmacy registered under s. 465.0156
 146 which ships, mails, delivers, or dispenses a compounded sterile
 147 product into this state may continue to do so if the product
 148 meets or exceeds the standards for sterile compounding in this
 149 state, the product is not compounded in violation of any law or
 150 rule of the state, territory, or district where the pharmacy is
 151 located, and the pharmacy is issued a permit under this section
 152 on or before March 1, 2015.
 153 (7) An applicant registering on or after October 1, 2014,
 154 as a nonresident pharmacy under s. 465.0156 may not ship, mail,
 155 deliver, or dispense a compounded sterile product into this
 156 state until the applicant is registered as a nonresident

157 pharmacy and is issued a permit under this section.

158 (8) The board shall adopt rules as necessary to administer
 159 this section, including rules for:

160 (a) Submitting an application for the permit required by
 161 this section.

162 (b) Determining how, when, and under what circumstances an
 163 inspection of a nonresident sterile compounding permittee must
 164 be conducted.

165 (c) Evaluating and approving entities from which a
 166 satisfactory inspection report will be accepted in lieu of an
 167 onsite inspection by the department or an inspection by the
 168 licensing or regulatory agency of the state, territory, or
 169 district where the applicant is located.

170 Section 4. Section 465.017, Florida Statutes, is amended
 171 to read:

172 465.017 Authority to inspect; disposal.—

173 (1) Duly authorized agents and employees of the department
 174 ~~may shall have the power to~~ inspect in a lawful manner at all
 175 reasonable hours any pharmacy, hospital, clinic, wholesale
 176 establishment, manufacturer, physician's office, or any other
 177 place in the state in which drugs and medical supplies are
 178 compounded, manufactured, packed, packaged, made, stored, sold,
 179 offered for sale, exposed for sale, or kept for sale for the
 180 purpose of:

181 (a) Determining if any provision ~~of the provisions~~ of this
 182 chapter or any rule adopted ~~promulgated~~ under its authority is

183 being violated;

184 (b) Securing samples or specimens of any drug or medical
 185 supply after paying or offering to pay for such sample or
 186 specimen; or

187 (c) Securing such other evidence as may be needed for
 188 prosecution under this chapter.

189 (2) Duly authorized agents and employees of the department
 190 may inspect a nonresident pharmacy registered under s. 465.0156
 191 or a nonresident sterile compounding permittee under s. 465.0158
 192 pursuant to this section. The costs of such inspections shall be
 193 borne by such pharmacy or permittee.

194 (3)(2)(a) Except as permitted by this chapter, and
 195 chapters 406, 409, 456, 499, and 893, records maintained in a
 196 pharmacy relating to the filling of prescriptions and the
 197 dispensing of medicinal drugs may ~~shall not~~ be furnished only to
 198 ~~any person other than to~~ the patient for whom the drugs were
 199 dispensed, or her or his legal representative, or to the
 200 department pursuant to existing law, or, ~~if in the event that~~
 201 the patient is incapacitated or unable to request such ~~said~~
 202 records, her or his spouse except upon the written authorization
 203 of such patient.

204 (a) Such records may be furnished in any civil or criminal
 205 proceeding, upon the issuance of a subpoena from a court of
 206 competent jurisdiction and proper notice to the patient or her
 207 or his legal representative by the party seeking such records.

208 (b) The board shall adopt rules establishing ~~to establish~~

CS/HB 7077

2014

209 practice guidelines for pharmacies to dispose of records
210 maintained in a pharmacy relating to the filling of
211 prescriptions and the dispensing of medicinal drugs. Such rules
212 must ~~shall~~ be consistent with the duty to preserve the
213 confidentiality of such records in accordance with applicable
214 state and federal law.

215 Section 5. This act shall take effect October 1, 2014.